Opinion

Video

Moving Beyond The Joint: Unraveling Gout's Systemic and Renal Implications

Key opinion leaders analyze EULAR 2024 updates on gout, chronic inflammation's systemic impact, and gout-chronic kidney disease (CKD) connections, while examining urate-lowering therapies for gout management, particularly in patients with CKD.

Related Videos
Jennifer Flemming, MD | Credit: AASLD
3 experts are featured in this series.
John Kane, MD | Credit: Northwell Health
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
4 experts are featured in this series.
Related Content
Shashank Deshpande I Credit: LinkedIn
January 16th 2025

Iclepertin Fails to Improve Cognition in Schizophrenia Phase 3 Study

Chelsie Derman
Skin of Color Savvy: News Update—SOCS Awards, My Best Winter Skin, & TORPEDO Program
January 15th 2025

Skin of Color Savvy: News Update—SOCS Awards, My Best Winter Skin, & TORPEDO Program

Robert Brodell, MD
Reynold Panettieri, MD, vice chancellor for Translational Medicine and Science at Rutgers University,
January 16th 2025

Elevated Serum cAMP Findings May Allow Asthma Diagnosis by Blood Test

Victoria Johnson
Diabetes Dialogue: The Role of Dietitians in GLP-1 RA Use | Image Credit: HCPLive
January 13th 2025

Diabetes Dialogue: The Evolving Role of Registered Dietitian Nutritionists in Obesity

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
New Dosing Option for Bimekizumab Now Commercially Available for PsA, Psoriasis, HS
January 16th 2025

New Dosing Option for Bimekizumab Now Commercially Available for PsA, Psoriasis, HS

Tim Smith
FDA Approves Axatilimab 9 mg and 22 mg Vial Sizes for Chronic GVHD | Image Credit: US Food and Drug Administration
January 16th 2025

FDA Approves Axatilimab 9 mg and 22 mg Vial Sizes for Chronic GVHD

Connor Iapoce
© 2025 MJH Life Sciences

All rights reserved.